Please Wait.....
Report
U.S. Cryogenic Biobanking Services Market - Industry Outlook & Forecast 2025-2030
Market Report I 2025-02-25 I 246 Pages I Arizton Advisory & Intelligence
The U.S. cryogenic biobanking services is expected to grow at a CAGR of 5.85% from 2024 to 2030.
MARKET TRENDS & DRIVERS
Expansion of Virtual Biobanking
The expansion of virtual biobanking is a game-changer in the U.S. cryogenic biobanking services market. By bridging the gap between physical sample storage and digital data accessibility, it unlocks new potential for collaboration, research efficiency, and personalized medicine. With continued advancements and supportive regulatory frameworks, virtual biobanking will play a pivotal role in shaping the future of biomedical science.
Growing Conservation of Cord Blood Stem Cells of Newborns
The growing conservation of cord blood stem cells represents a transformative trend in the U.S. cryogenic biobanking services market. With its potential to revolutionize treatments for a wide range of diseases and its role in advancing regenerative medicine, cord blood banking is driving innovation and creating new opportunities for biobanking providers. By embracing this trend and overcoming associated challenges, the market is set to make significant contributions to healthcare and scientific advancements in the years to come.
Advancements in Cryopreservation Technology
Advancements in cryopreservation technology are revolutionizing the U.S. cryogenic biobanking services market, offering unprecedented opportunities for biomedical research, personalized medicine, and regenerative therapies. By enhancing the quality and longevity of biological samples, these innovations are driving progress in healthcare and opening new avenues for discovery. One of the most significant advancements in cryopreservation technology is the development of vitrification. This method involves ultra-rapid cooling, which prevents the formation of ice crystals that can damage cells, tissues, and other biological materials.
Emergence of Personalized Biobanking
With the rise of personalized medicine, the demand for tailored therapies and treatments is higher than ever, and biobanks are uniquely positioned to support this transformation. By providing valuable insights into individual health profiles, personalized biobanks are unlocking new opportunities in drug development, disease prevention, and precision medicine. Moreover, with the rapid progress in genomic technologies such as next-generation sequencing (NGS), personalized biobanks have become essential in the study of genomics and precision medicine. The ability to sequence an individual's genome and analyze genetic predispositions, disease risks, and drug responses is unlocking unprecedented opportunities in targeted therapies.
Rising Prevalence of Chronic Diseases
The rising prevalence of chronic diseases in the U.S. has significantly boosted the demand for cryogenic biobanking services. By providing essential resources for research, diagnostics, and therapeutics, biobanking serves as a cornerstone in addressing the chronic disease burden. As the healthcare landscape evolves, cryogenic biobanking is poised to remain a vital tool in advancing medical science, improving patient outcomes, and transforming the way chronic diseases are understood and treated.
Surge in Clinical Trials for New Drugs and Therapies
The surge in clinical trials for new drugs and therapies is undeniably a driving force in the U.S. cryogenic biobanking services market. As the demand for efficient sample storage and management continues to grow, cryogenic biobanking will remain at the forefront of medical research and innovation. By supporting the development of life-saving treatments and therapies, the biobanking market is not only fueling market growth but also contributing to the advancement of global healthcare.
Expansion of Genomics and Proteomics Research
The expansion of genomics and proteomics research is a driving force behind the growth of the United States cryogenic biobanking services market. By providing essential storage solutions for biological specimens, cryogenic biobanks are enabling groundbreaking discoveries in precision medicine, disease diagnostics, and therapeutic development. As these fields continue to evolve, the role of cryogenic biobanking will remain pivotal in advancing the frontiers of medical and biological research, ultimately transforming patient care and health outcomes.
Favorable Government and Private Funding
Favorable government and private funding have undeniably been key drivers of the U.S. cryogenic biobanking services market. By supporting infrastructure development, technological innovation, and collaborative research, these funding efforts have positioned the U.S. as a global leader in biobanking. Examples like the NIH's All of Us program and private sector partnerships highlight the profound impact of financial backing, paving the way for innovative breakthroughs and improved healthcare outcomes.
SEGMENTATION INSIGHTS
INSIGHTS BY SERVICE TYPE
The U.S. cryogenic biobanking services market by service type is segmented into biobanking & repository, validation/qualification, lab processing, and others. The biobanking and repository segment dominates the market, offering secure cryogenic storage solutions for biological samples, such as tissues, blood, and cell cultures. These services ensure the long-term preservation of biomaterials, supporting research, drug development, and clinical applications. Furthermore, the validation/qualification segment focuses on ensuring that biobanking systems and equipment meet regulatory and operational standards. It includes temperature validation, equipment qualification, and process monitoring, which are critical for maintaining sample integrity.
Lab processing services include sample preparation, aliquoting, nucleic acid extraction, and cryopreservation protocols. These services enhance the usability of stored samples for downstream applications in research and diagnostics. Moreover, others encompass ancillary services such as sample transportation, and custom biobank solutions, which support efficient operations in biobanking facilities.
Segmentation by Service Type
- Biobanking & Repository
- Validation/Qualification
- Lab Processing
- Others
INSIGHTS BY SAMPLE TYPE
The human samples sample type holds the largest share of the U.S. cryogenic biobanking services market in 2024, driven by the demand for human tissues, blood, DNA, and cell cultures in research, clinical trials, and drug development. Human samples are critical for precision medicine, epidemiology, and regenerative therapies. Blood and plasma are among the most commonly stored samples in cryogenic biobanks. These samples are critical for a wide range of applications, including disease diagnostics, biomarker discovery, and therapeutic monitoring.
Animal samples are primarily used in preclinical studies, veterinary research, and conservation biology. Cryogenic storage of animal tissues and cells enables advancements in toxicology, genomics, and ecosystem restoration. Furthermore, plant samples are crucial for agricultural research, genetic studies, and biodiversity conservation. Cryogenic storage of seeds, tissues, and plant cells ensures the preservation of genetic diversity and supports ecosystem sustainability.
Segmentation by Sample Type
- Human Samples
- Animal Samples
- Plant Samples
- Others
INSIGHTS BY APPLICATION
The U.S. cryogenic biobanking services market by application is segmented into drug discovery & development, regenerative medicine, epidemiology & population health, and conservation & ecosystem restoration. The drug discovery & development segment dominated the U.S. market share in 2024. Cryogenic biobanking supports pharmaceutical R&D by storing high-quality samples for target identification, biomarker validation, and clinical trials. It is integral to developing novel therapeutics and personalized medicine.
Regenerative medicine involves the preservation of stem cells, tissues, and organoids for regenerative therapies. Cryogenic biobanking plays a pivotal role in advancing cell-based treatments and organ transplantation research. Furthermore, biobanks store large-scale population samples, enabling epidemiological studies, disease surveillance, and public health interventions. These repositories support the analysis of disease trends and healthcare planning.
Segmentation by Application
- Drug Discovery & Development
- Regenerative Medicine
- Epidemiology & Population Health
- Conservation & Ecosystem Restoration
INSIGHTS BY OWNERSHIP
The U.S. cryogenic biobanking services market by ownership is segmented into universities, non-profit organizations, state/government agencies, and private organizations. The universities segment holds the largest U.S. market share. Universities manage biobanks for research and educational purposes, focusing on advancing scientific knowledge in genomics, precision medicine, and regenerative therapies. By integrating cryogenic biobanking services into their institutions, universities foster innovation while supporting academic and collaborative research efforts.
Furthermore, non-profit organizations focus on disease-specific research and population health. They manage biobanks that support public health studies, epidemiology, and translational research. Also, state/government agencies operate biobanks for public health, disease control, and conservation initiatives. These repositories ensure equitable access to resources for national healthcare and biodiversity goals. Private organizations cater to commercial sectors such as pharmaceuticals and biotechnology. They provide customized storage, processing, and validation services to support drug development and research.
Segmentation by Ownership
- Universities
- Non-profit Organizations
- State/Government Agencies
- Private Organizations
INSIGHTS BY END-USER
The pharma & biotech companies end-user holds the most prominent share of the U.S. cryogenic biobanking services market share. Pharma and biotech companies utilize biobanking services for R&D, clinical trials, and drug development. Cryogenic biobanks support the storage of biological samples, enabling innovation in therapeutics and diagnostics. Academic and research institutions leverage cryogenic biobanking for genomics, population health studies, and translational medicine. These biobanks drive scientific advancements and innovation. Furthermore, healthcare providers such as hospitals and healthcare facilities use biobanking services to store patient samples for diagnostic purposes, therapeutic applications, and personalized treatment planning. CROs & CDMOs utilize biobanking for preclinical studies, clinical trials, and biomanufacturing processes. Cryogenic biobanking supports their contract-based operations. Also, life sciences firms rely on cryogenic biobanking for biotechnology research, including the development of biosimilars, cell therapies, and molecular diagnostics. Other end-users include medical device companies, public health agencies, and donors/participants that use cryogenic biobanking for various specialized applications.
Segmentation by End-User
- Pharma & Biotech Companies
- Academic & Research Institutes
- Healthcare Providers
- CROs & CDMOs
- Life Sciences Companies
- Others
COMPETITIVE LANDSCAPE
The U.S. cryogenic biobanking services market is a dynamic and competitive sector, fueled by the rising demand for long-term preservation of biological specimens for research, clinical, and commercial purposes. The competitive landscape is characterized by the presence of established market leaders, emerging players, and niche service providers. Companies in this market compete based on factors such as technological innovation, service diversity, quality assurance, compliance with regulatory standards, and strategic partnerships. Furthermore, the United States cryogenic biobanking services market is dominated by several established players, including specialized service providers, contract biobanking companies, and academic and healthcare institutions offering cryogenic storage solutions.
Furthermore, to maintain their positions and attract new clients, companies in the U.S. cryogenic biobanking services market employ a variety of competitive strategies. For instance, companies are expanding their service portfolios to include additional offerings such as disaster recovery solutions, regulatory consulting, and data integration with laboratory information management systems (LIMS). Also, many firms prioritize flexibility in service offerings, such as custom biobanking solutions tailored to specific client requirements, to differentiate themselves in the market.
Company Profiles
- Azenta Life Sciences
- BioDock (Future Health Group)
- BioKryo
- BioRepository Resources (Tobin Scientific)
- Biostorage
- BocaBio
- Brigham and Women's Hospital Division of Preventive Medicine
- Cell Culture Company
- Cleveland Clinic
- Coriell Institute
- Cryo Bio System
- Cryoport Systems
- CRYOTHERM
- Cureline
- Custom BioGenic Systems
- Duke University and Duke University Health System
- Greiner Bio-One International GmbH
- Kaiser Permanente
- Mayo Clinic
- Northwestern University
- Personalized Stem Cells
- Precision Stability Storage
- REPROCELL
- Rhode Island Biobank (Brown University)
- RUSH University
- Sampled
- SCISAFE
- SPT Labtech
- Stanford University
- Tecan Trading AG
- The Johns Hopkins University
- The University of Arizona
- The University of Chicago Medical Center
- The University of Iowa
- The University of Pennsylvania
- The University of Texas MD Anderson Cancer Center
- Thermo Fisher Scientific
- Thermogenesis Holdings
- University of South Alabama
- Washington University
- WiCell
- Yale School of Medicine
KEY QUESTIONS ANSWERED:
1. Which sample type dominates the U.S. cryogenic biobanking services market share?
2. How big is the U.S. cryogenic biobanking services market?
3. What is the growth rate of the U.S. cryogenic biobanking services market?
4. What are the significant trends in the U.S. cryogenic biobanking services market?
1. SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET SEGMENTATION COVERAGE & DEFINITIONS
1.2.1. MARKET BY SERVICE TYPE
1.2.2. MARKET BY SAMPLE TYPE
1.2.3. MARKET BY APPLICATION
1.2.4. MARKET BY OWNERSHIP
1.2.5. MARKET BY END-USER
1.2.6. COUNTRIES COVERED
1.3. MARKET DERIVATION
1.3.1. BASE YEAR
2. PREMIUM INSIGHTS
2.1. OPPORTUNITY POCKETS
2.2. OVERVIEW
3. MARKET AT A GLANCE
4. INTRODUCTION
4.1. OVERVIEW
5. MARKET OPPORTUNITIES & TRENDS
5.1. GROWING CONSERVATION OF CORD BLOOD STEM CELLS OF NEWBORNS
5.2. EXPANSION OF VIRTUAL BIOBANKING
5.3. ADVANCES IN CRYOPRESERVATION TECHNOLOGY
5.4. EMERGENCE OF PERSONALIZED BIOBANKING
6. MARKET GROWTH ENABLERS
6.1. RISING PREVALENCE OF CHRONIC DISEASES
6.2. SURGE IN CLINICAL TRIALS FOR NEW DRUGS AND THERAPIES
6.3. EXPANSION OF GENOMICS AND PROTEOMICS RESEARCH
6.4. FAVORABLE GOVERNMENT AND PRIVATE FUNDING
7. MARKET RESTRAINTS
7.1. HIGH OPERATIONAL COSTS
7.2. ETHICAL CONCERNS AND CONSENT MANAGEMENT
7.3. SAMPLE QUALITY AND VIABILITY RISKS
8. MARKET LANDSCAPE
8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
8.3.1. THREAT OF NEW ENTRANTS
8.3.2. BARGAINING POWER OF SUPPLIERS
8.3.3. BARGAINING POWER OF BUYERS
8.3.4. THREAT OF SUBSTITUTES
8.3.5. COMPETITIVE RIVALRY
9. SERVICE TYPE
9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. BIOBANKING & REPOSITORY
9.3.1. MARKET OVERVIEW
9.3.2. MARKET SIZE & FORECAST
9.4. VALIDATION/QUALIFICATION
9.4.1. MARKET OVERVIEW
9.4.2. MARKET SIZE & FORECAST
9.5. LAB PROCESSING
9.5.1. MARKET OVERVIEW
9.5.2. MARKET SIZE & FORECAST
9.6. OTHERS
9.6.1. MARKET OVERVIEW
9.6.2. MARKET SIZE & FORECAST
10. SAMPLE TYPE
10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. HUMAN SAMPLES
10.3.1. MARKET OVERVIEW
10.3.2. MARKET SIZE & FORECAST
10.4. ANIMAL SAMPLES
10.4.1. MARKET OVERVIEW
10.4.2. MARKET SIZE & FORECAST
10.5. PLANT SAMPLES
10.5.1. MARKET OVERVIEW
10.5.2. MARKET SIZE & FORECAST
10.6. OTHERS
10.6.1. MARKET OVERVIEW
10.6.2. MARKET SIZE & FORECAST
11. APPLICATION
11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. DRUG DISCOVERY & DEVELOPMENT
11.3.1. MARKET OVERVIEW
11.3.2. MARKET SIZE & FORECAST
11.4. REGENERATIVE MEDICINE
11.4.1. MARKET OVERVIEW
11.4.2. MARKET SIZE & FORECAST
11.5. EPIDEMIOLOGY & POPULATION HEALTH
11.5.1. MARKET OVERVIEW
11.5.2. MARKET SIZE & FORECAST
11.6. CONSERVATION & ECOSYSTEM RESTORATION
11.6.1. MARKET OVERVIEW
11.6.2. MARKET SIZE & FORECAST
12. OWNERSHIP
12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. MARKET OVERVIEW
12.3. UNIVERSITIES
12.3.1. MARKET OVERVIEW
12.3.2. MARKET SIZE & FORECAST
12.4. NON-PROFIT ORGANIZATIONS
12.4.1. MARKET OVERVIEW
12.4.2. MARKET SIZE & FORECAST
12.5. STATE/GOVERNMENT AGENCIES
12.5.1. MARKET OVERVIEW
12.5.2. MARKET SIZE & FORECAST
12.6. PRIVATE ORGANIZATIONS
12.6.1. MARKET OVERVIEW
12.6.2. MARKET SIZE & FORECAST
13. END-USERS
13.1. MARKET SNAPSHOT & GROWTH ENGINE
13.2. MARKET OVERVIEW
13.3. PHARMA & BIOTECH COMPANIES
13.3.1. MARKET OVERVIEW
13.3.2. MARKET SIZE & FORECAST
13.4. ACADEMIC & RESEARCH INSTITUTES
13.4.1. MARKET OVERVIEW
13.4.2. MARKET SIZE & FORECAST
13.5. HEALTHCARE PROVIDERS
13.5.1. MARKET OVERVIEW
13.5.2. MARKET SIZE & FORECAST
13.6. CROS AND CDMOS
13.6.1. MARKET OVERVIEW
13.6.2. MARKET SIZE & FORECAST
13.7. LIFE SCIENCES COMPANIES
13.7.1. MARKET OVERVIEW
13.7.2. MARKET SIZE & FORECAST
13.8. OTHERS
13.8.1. MARKET OVERVIEW
13.8.2. MARKET SIZE & FORECAST
14. COMPETITIVE LANDSCAPE
14.1. COMPETITION OVERVIEW
15. COMPANY PROFILES
15.1. AZENTA LIFE SCIENCES
15.1.1. BUSINESS OVERVIEW
15.1.2. SERVICE OFFERINGS
15.2. BIODOCK (FUTURE HEALTH GROUP)
15.2.1. BUSINESS OVERVIEW
15.2.2. SERVICE OFFERINGS
15.3. BIOKRYO
15.3.1. BUSINESS OVERVIEW
15.3.2. SERVICE OFFERINGS
15.4. BIOREPOSITORY RESOURCES (TOBIN SCIENTIFIC)
15.4.1. BUSINESS OVERVIEW
15.4.2. SERVICE OFFERINGS
15.5. BIOSTORAGE
15.5.1. BUSINESS OVERVIEW
15.5.2. SERVICE OFFERINGS
15.6. BOCABIO
15.6.1. BUSINESS OVERVIEW
15.6.2. SERVICE OFFERINGS
15.7. BRIGHAM AND WOMEN'S HOSPITAL DIVISION OF PREVENTIVE MEDICINE
15.7.1. BUSINESS OVERVIEW
15.7.2. SERVICE OFFERINGS
15.8. CELL CULTURE COMPANY
15.8.1. BUSINESS OVERVIEW
15.8.2. SERVICE OFFERINGS
15.9. CLEVELAND CLINIC
15.9.1. BUSINESS OVERVIEW
15.9.2. SERVICE OFFERINGS
15.10. CORIELL INSTITUTE
15.10.1. BUSINESS OVERVIEW
15.10.2. SERVICE OFFERINGS
15.11. CRYO BIOSYSTEM
15.11.1. BUSINESS OVERVIEW
15.11.2. SERVICE OFFERINGS
15.12. CRYOPORT SYSTEMS
15.12.1. BUSINESS OVERVIEW
15.12.2. SERVICE OFFERINGS
15.13. CRYOTHERM
15.13.1. BUSINESS OVERVIEW
15.13.2. SERVICE OFFERINGS
15.14. CURELINE
15.14.1. BUSINESS OVERVIEW
15.14.2. SERVICE OFFERINGS
15.15. CUSTOM BIOGENIC SYSTEMS
15.15.1. BUSINESS OVERVIEW
15.15.2. SERVICE OFFERINGS
15.16. DUKE UNIVERSITY AND DUKE UNIVERSITY HEALTH SYSTEM
15.16.1. BUSINESS OVERVIEW
15.16.2. SERVICE OFFERINGS
15.17. GREINER BIO-ONE INTERNATIONAL GMBH
15.17.1. BUSINESS OVERVIEW
15.17.2. SERVICE OFFERINGS
15.18. KAISER PERMANENTE
15.18.1. BUSINESS OVERVIEW
15.18.2. SERVICE OFFERINGS
15.19. MAYO CLINIC
15.19.1. BUSINESS OVERVIEW
15.19.2. SERVICE OFFERINGS
15.20. NORTHWESTERN UNIVERSITY
15.20.1. BUSINESS OVERVIEW
15.20.2. SERVICE OFFERINGS
15.21. PERSONALIZED STEM CELLS
15.21.1. BUSINESS OVERVIEW
15.21.2. SERVICE OFFERINGS
15.22. PRECISION STABILITY STORAGE
15.22.1. BUSINESS OVERVIEW
15.22.2. SERVICE OFFERINGS
15.23. REPROCELL
15.23.1. BUSINESS OVERVIEW
15.23.2. SERVICE OFFERINGS
15.24. RHODE ISLAND BIOBANK (BROWN UNIVERSITY)
15.24.1. BUSINESS OVERVIEW
15.24.2. SERVICE OFFERINGS
15.25. RUSH UNIVERSITY
15.25.1. BUSINESS OVERVIEW
15.25.2. SERVICE OFFERINGS
15.26. SAMPLED
15.26.1. BUSINESS OVERVIEW
15.26.2. SERVICE OFFERINGS
15.27. SCISAFE
15.27.1. BUSINESS OVERVIEW
15.27.2. SERVICE OFFERINGS
15.28. SPT LABTECH
15.28.1. BUSINESS OVERVIEW
15.28.2. SERVICE OFFERINGS
15.29. STANFORD UNIVERSITY
15.29.1. BUSINESS OVERVIEW
15.29.2. SERVICE OFFERINGS
15.30. TECAN TRADING AG
15.30.1. BUSINESS OVERVIEW
15.30.2. SERVICE OFFERINGS
15.31. THE JOHNS HOPKINS UNIVERSITY
15.31.1. BUSINESS OVERVIEW
15.31.2. SERVICE OFFERINGS
15.32. THE UNIVERSITY OF ARIZONA
15.32.1. BUSINESS OVERVIEW
15.32.2. SERVICE OFFERINGS
15.33. THE UNIVERSITY OF CHICAGO MEDICAL CENTER
15.33.1. BUSINESS OVERVIEW
15.33.2. SERVICE OFFERINGS
15.34. THE UNIVERSITY OF IOWA
15.34.1. BUSINESS OVERVIEW
15.34.2. SERVICE OFFERINGS
15.35. THE UNIVERSITY OF PENNSYLVANIA
15.35.1. BUSINESS OVERVIEW
15.35.2. SERVICE OFFERINGS
15.36. THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
15.36.1. BUSINESS OVERVIEW
15.36.2. SERVICE OFFERINGS
15.37. THERMO FISHER SCIENTIFIC
15.37.1. BUSINESS OVERVIEW
15.37.2. SERVICE OFFERINGS
15.38. THERMOGENESIS HOLDINGS
15.38.1. BUSINESS OVERVIEW
15.38.2. SERVICE OFFERINGS
15.39. UNIVERSITY OF SOUTH ALABAMA
15.39.1. BUSINESS OVERVIEW
15.39.2. SERVICE OFFERINGS
15.40. WASHINGTON UNIVERSITY
15.40.1. BUSINESS OVERVIEW
15.40.2. SERVICE OFFERINGS
15.41. WICELL
15.41.1. BUSINESS OVERVIEW
15.41.2. SERVICE OFFERINGS
15.42. YALE SCHOOL OF MEDICINE
15.42.1. BUSINESS OVERVIEW
15.42.2. SERVICE OFFERINGS
16. REPORT SUMMARY
16.1. KEY TAKEAWAYS
16.2. STRATEGIC RECOMMENDATIONS
17. QUANTITATIVE SUMMARY
17.1. MARKET BY SERVICE TYPE
17.2. MARKET BY SAMPLE TYPE
17.3. MARKET BY APPLICATION
17.4. MARKET BY OWNERSHIP
17.5. MARKET BY END-USER
18. APPENDIX
18.1. RESEARCH METHODOLOGY
18.2. RESEARCH PROCESS
18.3. REPORT ASSUMPTIONS & CAVEATS
18.3.1. KEY CAVEATS
18.3.2. CURRENCY CONVERSION
18.4. ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 MARKET SIZE CALCULATION APPROACH (2024)
EXHIBIT 2 US CRYOGENIC BIOBANKING SERVICES MARKET BY SERVICE TYPE: MARKET SHARE (2024 & 2030)
EXHIBIT 3 US CRYOGENIC BIOBANKING SERVICES MARKET BY SAMPLE TYPE: MARKET SHARE (2024 & 2030)
EXHIBIT 4 US CRYOGENIC BIOBANKING SERVICES MARKET BY APPLICATION: MARKET SHARE (2024 & 2030)
EXHIBIT 5 US CRYOGENIC BIOBANKING SERVICES MARKET BY OWNERSHIP: MARKET SHARE (2024 & 2030)
EXHIBIT 6 US CRYOGENIC BIOBANKING SERVICES MARKET BY END-USER: MARKET SHARE (2024 & 2030)
EXHIBIT 7 IMPACT OF GROWING CONSERVATION OF CORD BLOOD STEM CELLS OF NEWBORNS
EXHIBIT 8 IMPACT OF EXPANSION OF VIRTUAL BIOBANKING
EXHIBIT 9 IMPACT OF ADVANCES IN CRYOPRESERVATION TECHNOLOGY
EXHIBIT 10 IMPACT OF EMERGENCE OF PERSONALIZED BIOBANKING
EXHIBIT 11 IMPACT OF RISING PREVALENCE OF CHRONIC DISEASES
EXHIBIT 12 IMPACT OF SURGE IN CLINICAL TRIALS FOR NEW DRUGS AND THERAPIES
EXHIBIT 13 IMPACT OF EXPANSION OF GENOMICS AND PROTEOMICS RESEARCH
EXHIBIT 14 IMPACT OF FAVORABLE GOVERNMENT AND PRIVATE FUNDING
EXHIBIT 15 IMPACT OF HIGH OPERATIONAL COSTS
EXHIBIT 16 IMPACT OF ETHICAL CONCERNS AND CONSENT MANAGEMENT
EXHIBIT 17 IMPACT OF SAMPLE QUALITY AND VIABILITY RISKS
EXHIBIT 18 US CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 19 FIVE FORCES ANALYSIS (2024)
EXHIBIT 20 INCREMENTAL GROWTH BY SERVICE TYPE (2024 & 2030)
EXHIBIT 21 US CRYOGENIC BIOBANKING SERVICES MARKET BY SERVICE TYPE 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 22 US CRYOGENIC BIOBANKING SERVICES MARKET BY SERVICE TYPE 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 23 US BIOBANKING & REPOSITORY CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 24 US BIOBANKING & REPOSITORY CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 25 US VALIDATION/QUALIFICATION CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 26 US VALIDATION/QUALIFICATION CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 27 US LAB PROCESSING CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 US LAB PROCESSING CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 29 US OTHER CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 US OTHER CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 31 INCREMENTAL GROWTH BY SAMPLE TYPE (2024 & 2030)
EXHIBIT 32 US CRYOGENIC BIOBANKING SERVICES MARKET BY SAMPLE TYPE 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 33 US CRYOGENIC BIOBANKING SERVICES MARKET BY SAMPLE TYPE 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 34 US HUMAN SAMPLE CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 35 US HUMAN SAMPLE CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 36 US ANIMAL SAMPLE CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 US ANIMAL SAMPLE CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 38 US PLANT SAMPLE CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 US PLANT SAMPLE CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 40 US OTHER CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 US OTHER CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 42 INCREMENTAL GROWTH BY APPLICATION (2024 & 2030)
EXHIBIT 43 US CRYOGENIC BIOBANKING SERVICES MARKET BY APPLICATION 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 44 US CRYOGENIC BIOBANKING SERVICES MARKET BY APPLICATION 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 45 US DRUG DISCOVERY & DEVELOPMENT CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 US DRUG DISCOVERY & DEVELOPMENT CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 47 US REGENERATIVE MEDICINE CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 US REGENERATIVE MEDICINE CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 49 US EPIDEMIOLOGY & POPULATION HEALTH CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 US EPIDEMIOLOGY & POPULATION HEALTH CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 51 US CONSERVATION & ECOSYSTEM RESTORATION CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 US CONSERVATION & ECOSYSTEM RESTORATION CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 53 INCREMENTAL GROWTH BY OWNERSHIP (2024 & 2030)
EXHIBIT 54 US CRYOGENIC BIOBANKING SERVICES MARKET BY OWNERSHIP 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 55 US CRYOGENIC BIOBANKING SERVICES MARKET BY OWNERSHIP 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 56 US UNIVERSITIES CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 US UNIVERSITIES CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 58 US NON-PROFIT ORGANIZATIONS CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 US NON-PROFIT ORGANIZATIONS CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 60 US STATE/GOVERNMENT AGENCIES CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 US STATE/GOVERNMENT AGENCIES CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 62 US PRIVATE ORGANIZATIONS CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 US PRIVATE ORGANIZATIONS CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 64 INCREMENTAL GROWTH BY END-USERS (2024 & 2030)
EXHIBIT 65 US CRYOGENIC BIOBANKING SERVICES MARKET BY END-USER 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 66 US CRYOGENIC BIOBANKING SERVICES MARKET BY END-USER 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 67 US PHARMA & BIOTECH COMPANIES CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 68 US PHARMA & BIOTECH COMPANIES CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 69 US ACADEMIC & RESEARCH INSTITUTES CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 US ACADEMIC & RESEARCH INSTITUTES CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 71 US HEALTHCARE PROVIDERS CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 US HEALTHCARE PROVIDERS CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 73 US CROS & CDMOS CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 74 US CROS & CDMOS CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 75 US LIFE SCIENCES COMPANIES CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 76 US LIFE SCIENCES COMPANIES CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 77 US OTHER CRYOGENIC BIOBANKING SERVICES MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 78 US OTHER CRYOGENIC BIOBANKING SERVICES MARKET 2021-2030 ($ BILLION)
EXHIBIT 79 KEY CAVEATS
LIST OF TABLES
TABLE 1 AZENTA LIFE SCIENCES: MAJOR SERVICE OFFERINGS
TABLE 2 BIODOCK: MAJOR SERVICE OFFERINGS
TABLE 3 BIOKRYO: MAJOR SERVICE OFFERINGS
TABLE 4 BIOREPOSITORY RESOURCES: MAJOR SERVICE OFFERINGS
TABLE 5 BIOSTORAGE: MAJOR SERVICE OFFERINGS
TABLE 6 BOCABIO: MAJOR SERVICE OFFERINGS
TABLE 7 BRIGHAM AND WOMEN'S HOSPITAL DIVISION OF PREVENTIVE MEDICINE: MAJOR SERVICE OFFERINGS
TABLE 8 CELL CULTURE COMPANY: MAJOR SERVICE OFFERINGS
TABLE 9 CLEVELAND CLINIC: MAJOR SERVICE OFFERINGS
TABLE 10 CORIELL INSTITUTE: MAJOR SERVICE OFFERINGS
TABLE 11 CRYO BIO SYSTEM: MAJOR SERVICE OFFERINGS
TABLE 12 CRYOPORT SYSTEMS: MAJOR SERVICE OFFERINGS
TABLE 13 CRYOTHERM: MAJOR SERVICE OFFERINGS
TABLE 14 CURELINE: MAJOR SERVICE OFFERINGS
TABLE 15 CUSTOM BIOGENIC SYSTEMS: MAJOR SERVICE OFFERINGS
TABLE 16 DUKE UNIVERSITY AND DUKE UNIVERSITY HEALTH SYSTEM: MAJOR SERVICE OFFERINGS
TABLE 17 GREINER BIO-ONE INTERNATIONAL GMBH: MAJOR SERVICE OFFERINGS
TABLE 18 KAISER PERMANENTE: MAJOR SERVICE OFFERINGS
TABLE 19 MAYO CLINIC: MAJOR SERVICE OFFERINGS
TABLE 20 NORTHWESTERN UNIVERSITY: MAJOR SERVICE OFFERINGS
TABLE 21 PERSONALIZED STEM CELLS: MAJOR SERVICE OFFERINGS
TABLE 22 PRECISION STABILITY STORAGE: MAJOR SERVICE OFFERINGS
TABLE 23 REPROCELL: MAJOR SERVICE OFFERINGS
TABLE 24 RHODE ISLAND BIOBANK: MAJOR SERVICE OFFERINGS
TABLE 25 RUSH UNIVERSITY: MAJOR SERVICE OFFERINGS
TABLE 26 SAMPLED: MAJOR SERVICE OFFERINGS
TABLE 27 SCISAFE: MAJOR SERVICE OFFERINGS
TABLE 28 SPT LABTECH: MAJOR SERVICE OFFERINGS
TABLE 29 STANFORD UNIVERSITY: MAJOR SERVICE OFFERINGS
TABLE 30 TECAN TRADING AG: MAJOR SERVICE OFFERINGS
TABLE 31 THE JOHNS HOPKINS UNIVERSITY: MAJOR SERVICE OFFERINGS
TABLE 32 THE UNIVERSITY OF ARIZONA.: MAJOR SERVICE OFFERINGS
TABLE 33 THE UNIVERSITY OF CHICAGO MEDICAL CENTER: MAJOR SERVICE OFFERINGS
TABLE 34 THE UNIVERSITY OF IOWA: MAJOR SERVICE OFFERINGS
TABLE 35 THE UNIVERSITY OF PENNSYLVANIA (PENN MEDICINE BIOBANK): MAJOR SERVICE OFFERINGS
TABLE 36 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER: MAJOR SERVICE OFFERINGS
TABLE 37 THERMO FISHER SCIENTIFIC: MAJOR SERVICE OFFERINGS
TABLE 38 THERMOGENESIS HOLDINGS: MAJOR SERVICE OFFERINGS
TABLE 39 UNIVERSITY OF SOUTH ALABAMA: MAJOR SERVICE OFFERINGS
TABLE 40 WASHINGTON UNIVERSITY: MAJOR SERVICE OFFERINGS
TABLE 41 WICELL: MAJOR SERVICE OFFERINGS
TABLE 42 YALE SCHOOL OF MEDICINE: MAJOR SERVICE OFFERINGS
TABLE 43 US CRYOGENIC BIOBANKING SERVICES MARKET BY SERVICE TYPE 2024?2030 ($ BILLION)
TABLE 44 US CRYOGENIC BIOBANKING SERVICES MARKET BY SERVICE TYPE 2024?2030 (%)
TABLE 45 US CRYOGENIC BIOBANKING SERVICES MARKET BY SAMPLE TYPE 2024?2030 ($ BILLION)
TABLE 46 US CRYOGENIC BIOBANKING SERVICES MARKET BY SAMPLE TYPE 2024?2030 (%)
TABLE 47 US CRYOGENIC BIOBANKING SERVICES MARKET BY APPLICATION 2024?2030 ($ BILLION)
TABLE 48 US CRYOGENIC BIOBANKING SERVICES MARKET BY APPLICATION 2024?2030 (%)
TABLE 49 US CRYOGENIC BIOBANKING SERVICES MARKET BY OWNERSHIP 2024?2030 ($ BILLION)
TABLE 50 US CRYOGENIC BIOBANKING SERVICES MARKET BY OWNERSHIP 2024?2030 (%)
TABLE 51 US CRYOGENIC BIOBANKING SERVICES MARKET BY END-USER 2024?2030 ($ BILLION)
TABLE 52 US CRYOGENIC BIOBANKING SERVICES MARKET BY END-USER 2024?2030 (%)
TABLE 53 CURRENCY CONVERSION 2018?2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security